The U.S. Government Just Made Its Biggest Bet on Healthy Aging: Inside ARPA-H’s $144 Million PROSPR Program
ARPA-H’s $144 million PROSPR program is testing rapamycin, semaglutide, and dapagliflozin in 726 healthy older adults, funding a first-in-humans trial of a retrotransposon-silencing HIV drug, and building a validated biological…
